



#Courage #Compassion #Culture

2021 Annual Meeting

November 17-21 | **VIRTUAL MEETING**

ABSTRACT BOOK

astmh.org | ajtmh.org
 #TropMed21 #IamTropMed

Supplement to
The American Journal of Tropical Medicine and Hygiene



IMMUNOLOGICAL EVALUATION AND COMPARISON OF DIFFERENT CACHE VALLEY VIRUS VACCINE CANDIDATES

Victoria B. Ayers¹, Yan-Jang S. Huang¹, Alain Kohl², James I. Dunlop², So Lee Park¹, Stephen Higgs³, Dana L. Vanlandingham¹

¹Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States, ²MRC-University of Glasgow Centre for Virus Research, Glasgow G12 8QQ, United Kingdom, ³Biosecurity Research Institute, Kansas State University, Manhattan, KS, United States

Cache Valley virus (CVV; genus *Orthobunyavirus*, family *Peribunyaviridae*), first isolated in Cache Valley, Utah in 1956, is now enzootic throughout the New World. Although transmission of CVV occurs through an enzootic cycle including more than 30 species of competent arthropod vectors, serological evidence has indicated white-tailed deer as the amplification host for the virus in nature. Whilst CVV is primarily known to cause severe disease in pregnant ruminants resulting in abortions, fetal malformations, and embryonic lethality, it has also been recently recognized for its expansion as a zoonotic pathogen. Other viruses in the bunyamwera serogroup are thought to be of minimal concern. However, during an outbreak of Rift Valley fever virus, Ngari virus was found to have infected some of the goats being tested, and Oropouche virus, has been responsible for febrile disease outbreaks in Central and South America. With this increased emergence of bunyaviruses with human and veterinary health importance, there have been significant efforts dedicated to the development of bunyavirus vaccines. In this study, immunogenicity of a CVV vaccine candidate based on the deletion of NSs and NSm genes was evaluated and compared to a vaccine candidate created through the inactivation of CVV using binary ethylenimine with the addition of an aluminum hydroxide adjuvant in sheep. Immunization of 20 sheep with one of the two vaccine candidates was performed followed by two booster immunizations. Plaque reduction neutralization test was then used to monitor the development of neutralizing antibodies elicited by each vaccine candidate. The development of a vaccine for ruminants could lead to less human exposure and a platform for CVV and other emerging bunyaviruses that have already or could potentially cause future outbreaks.

ENSEMBLE MACHINE LEARNING METHOD AS A HIGH ACCURACY APPROACH TO COVID-19 SIMULATION

Dmytro Chumachenko¹, Ievgen Meniailov¹, Megan W. Howard², Kseniia Bazilevych¹, Lyubov Makhota³, Tetyana Chumachenko⁴

¹National Aerospace University Kharkiv Aviation Institute, Kharkiv, Ukraine, ²Battelle, Columbus, OH, United States, ³Kharkiv Regional Laboratory Center of the Ministry of Health of Ukraine, Kharkiv, Ukraine, ⁴Kharkiv National Medical University, Kharkiv, Ukraine

The COVID-19 pandemic shows that only timely implemented scientifically based measures can stop it. Mathematical modeling is an effective tool for studying the epidemic process. However, models suffer from low accuracy and are short-term in nature. Ensemble machine learning methods help optimize predictive models by combining several base models of epidemic processes. Different modeling approaches have different disadvantages, but their combined use makes it possible to eliminate these drawbacks. We used ensemble machine learning models to see if we could improve the accuracy of COVID-19 morbidity forecasting using data provided by the Coronavirus Resource Center of John Hopkins University & Medicine. The result was a cluster analysis method grouping countries based on similar COVID-19 morbidity characteristics, forecasting COVID-19 morbidity for each group using neural network, and combining the results into one country database. For clusterization we developed a neural network with 60 input neurons, 100 hidden neurons with Fermi activation function, and 4 output neurons. For forecasting, a neural network was built with 6 pairs of layers Dense with an activation function ReLu and 64 neurons, a layer Dropout and the last layer Dense with one output, RMSProp method as optimizer and Mean Squared Error as error function.

The final ensemble machine learning model was realized using Python programming. Employing ensemble machine learning model, we improved the accuracy of the forecast of COVID-19 morbidity to 98.11% compared to other models with accuracy of 85.12% (compartment models) or 87.30% (machine learning based models). High accuracy forecasting will improve the investigation of short-term dynamics and long-term trends of COVID-19 epidemic processes. In turn, this will allow for timely implementation of scientifically grounded measures to decrease COVID-19 dynamics. These results indicate that ensemble machine learning is useful tool for understanding the main drivers of COVID-19 dynamics and may better inform decision-making processes to prevent new waves of morbidity and deterioration of the epidemic situation.

COVID-19 SEROSURVEYS IN MASSACHUSETTS: CALL FOR ACTION

Raquel A. Binder¹, Catherine S. Forconi¹, Gavin F. Fujimori¹, Amanda Higgins¹, Virginia Mangolds¹, Thomas Nixon¹, Leandro DeSouza Silva¹, Priya Saikumar Lakshmi¹, Quishi Tang¹, Boaz Odwar¹, Stephanie Fischinger², Caroline Atyeo², Lisa Cavacini³, John Haran¹, Galit Alter⁴, Ann M. Moormann¹

¹UMass Medical School, Worcester, MA, United States, ²Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States, ³MassBiologics at UMass Medical School, Worcester, MA, United States, ⁴Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States

Seroprevalence studies (i.e. serosurveys) are essential public health tools that help determine the extent of an infectious disease outbreak and map its distribution among specific populations. COVID-19 serosurveys are particularly important, because (i) they capture asymptomatic infections, which are thought to account for 40-45% of all SARS-CoV-2 infections, and (ii) they indicate the level of existing immunity among affected populations. We implemented a laboratory developed test (LDT) that measures IgM, IgG and IgA antibodies by ELISA against the SARS-CoV-2 Spike Receptor Binding Domain (RBD) to determine the seroprevalence among health care workers (HCW) and return-to-work employees (RTW) at the University of Massachusetts Medical School. We enrolled and collected blood from 553 HCWs between April 27 and June 4, 2020 and 335 RTWs between Aug 3 and Aug 6, 2020. Our initial findings based on RBD IgG antibody levels, which is the most specific compared to PCR-confirmed cases, found a 14.1 % and 5.3 % seropositivity among HCWs and RTWs, respectively. The correlation between IgG and IgA levels was modest ($r=0.4$, Spearman Correlation, $p<0.0001$), supporting other studies that have shown divergent development of IgA in lieu of IgG for this respiratory infection. In contrast, IgM was the least sensitive and specific as a serosurveillance metric. As expected, we found that the overall positivity was higher among HCWs who were at higher risk of SARS-CoV-2 exposure as compared to employees who had been working remotely. This LDT ELISA has also been adapted for nucleocapsid and spike trimer protein in order to compare the sensitivity and specificity of each antigen and isotype, alone and in combination. In summary, we found that most of the HCWs and RTWs who enrolled in our study did not have antibodies to RBD, emphasizing the need for vaccines in order to reach population-wide immunity. This study shows that it is possible for academic medical centers to rapidly deploy LDTs and contribute to public health surveillance strategies for COVID-19.

The number(s) following author name refers to the abstract number.

- Chan, Adeline 0308, 0565
 Chan, Grace J. 0951, 0963
 Chanda, Kanij F. 0093
 Chandler, Claire 1070
 Chandler, Clare 0952
 Chandler, Clare I. 0505, 0775
 Chandler, Clare I. R. 0077
 Chandramohan, Daniel 0418, 1281
 Chandrashekar, Valleesha 1053
 Chandra Tangudu, Chandra 0174
 Chang, Judy 0789
 Chang, Stewart 1043
 Changalucha, John M. 1282
 Changjowk, Awin 0154
 Chann, Soklyda 1062
 Chansamouth, Vilada 0774, 0781
 Chaponda, Limbikani 0482
 Chaponda, Mike 0242, 0313, 0559, 1180
 Charles, Jermilia 0889
 Charles, Richelle C. 1296
 Charlotin, Marie Carmelle 0291
 Charurat, Manhattan 0022
 Chatel-Chaix, Laurent 1291
 Chattaway, Marie 0425
 Chavarria, Max 0479
 Chavchich, Marina 0884
 Chaves, Barbara 1009
 Chaves, Bárbara A. 0558
 Chavez, Chris 1317
 Chávez, Christian 0163
 Chaw, Kevin 1196
 Chawla, Tabish 0342
 Chazal, Maxime 0180
 Chea, Huch 0907, 1359
 Chea, Sophana 0907, 1305, 1359, 1362
 Cheah, Phaik Yeong **0508**
 Chebii, Philip 0140, 0580
 Chebii, Phillip K. 1025
 Checkley, Lisa 0246
 Checkley, Lisa A. 0412, 0667, 0674, 0855, 0924, 1067, 1069
 Cheeba, Maina 1265
 Cheeseman, Ian 0246
 Cheeseman, Ian H. 0412, 0413, 0667, 0924, 1067, 1069
 Cheeseman, Ian H. H. 0674
 Chelebieva, Sevil 0197
 Chellappah, Jessica 0875
 Che Mendoza, Azael 1304
 Che-Mendoza, Azael 0575
 Chen, Haily 0654
 Chen, James 0024
 Chen, Jean 1033
 Chen, Jian-Hua 1404
 Chen, Maria 0807
 Chen, Rebecca 1240, 1376
 Chen, Robert 0832
 Chen, Sharon 0696, 0926
 Chen, Shicheng **1016**
 Chen, Wen_Hsiang 1228
 Chen, Yihui 1254
 Chen, Yitong 1314
 Chen, Ze 0044
 Cheng, Qiuying 0017, 0187, 0251, 0252, **0608**, 0671, 0910, 1116, 1258, 1347, 1384, 1385
 Chenoweth, Josh G. **1208**
 Chenu, Elodie 0214
 Cherima, Yakubu 0211, 1133
 Cherkaoui, Mohammed 0218
 Chernet, Ambahun 1321
 Cheruiyot, Agnes 0198, 1060
 Chery, Ginette 0291
 Cheteug, Glwadys 0224
 Chevalley-Maurel, Severine 0193
 Chevalley-Maurel, Séverine 0292
 Chew, Robert 0920
 Chhonker, Yashpal S. 0483
 Chhorvann, Chhea 0147, 0156
 Chi, Socheat 0881
 Chibale, Kelly 0643
 Chibucos, Marcus 0615
 Chibwana, Alinafe 1390
 Chicca, Jeffrey **1241**
 Chico, R. Matthew 0725
 Chico, Rita 0282
 Chiduo, Mercy 0219
 Chidziwisano, Kondwani 0862
 Childs, David 0538
 Childs, Lauren 0999
 Chile, Nancy 0762
 Chilema, Ethel 1390
 Chilengi, Roma 0323
 Chilima, Ethel 0272
 Chilyabanyama, Obvious N. 0323
 Chimanya, Mabvuto 0366, 0774, 0903
 Chimumbwa, John 0739
 Chin, Deborah 1065
 Chinkhumba, Jobiba 0272, 1390
 Chinnawirotpisan, Piyawan 0613
 Chiodini, Peter 0371
 Chiphwanya, John 0482
 Chirwa, Tobias 0936
 Chisenga, Caroline C. 0323
 Chisenga, Mukosha 0739, **0844**
 Chisha, Terry 1100
 Chisti, Mohammad J. 0974
 Chisti, Mohammad J. 0390
 Chisti, Mohammad Jobayer 1199
 Chit Min, Myo 0464
 Chitnis, Nakul 0283, 0493, 0740
 Chitou, Said 0312
 Chiu, Charles 0469
 Chiyende, Elizabeth 1158
 Chiziba, Chilochibi 0260, **0261**
 Choi, Mary J. 0424
 Choi, Young-Jun 0401
 Chola, Namakau 0364
 Chomba, Elwyn 1109
 Cho-Ngwa, Fidelis 1231
 Chongwe, Gershom 0737, 1100
 Chop, Elisabeth 0037, 0798
 Chorazeczewski, Joanna K. 1048
 Chow, Eva 0183
 Chowdhury, Atique I. 0465, 0941, **0950**
 Chowdhury, Atique Iqbal 0084
 Chowdhury, Fahmida 0023, 0811
 Chowdhury, Fazle Rabbi 0367
 Chowdhury, Md. Atique I. 0461
 Chowdhury, Nayeem 0163, 1317
 Chowdhury, Rajashree 0379
 Chowell, Gerardo 1260
 Christian, D.a. 1406
 Christie, Athalia 0424
 Chu, Cindy 0629
 Chu, Cordia 0088
 Chu, Larry C. 0024
 Chu, May 0108, 0171
 Chu, Steven 0024
 Chu, Tzu-Chun 0006
 Chua, Joel V. 1289
 Chua, Kek Heng 0044
 Chughlay, Mohamed Farouk 0633
 Chukwu, Chimaobi 0022
 Chulkov, Evgeny G. 0404
 Chumachenko, Dmytro **0606**
 Chumachenko, Tetyana 0606
 Chunda, Valerie 1311
 Chung, Amy 0911
 Chung, Hye Kyung 0615
 Chung, Kevin 0468
 Chuquiyauri, Raul 0293
 Chuquiyauri Haro, Raul 0300
 Church, L.W. Preston 0300, 0422
 Church, LW P. 0687, 1118
 Church, Preston 0293
 Churcher, Thomas 1349
 Churcher, Thomas S. 0269, 0749
 Chutaró, Emi 0355
 Ciau-Carrilo, Karina J. 1304
 Ciccone, Emily J. 1325
 Ciglonecki, Iza 1144
 Ciloglu, Arzum 0208, 0509, 0719
 Cintron, Chelsie 0817, 1342, **1388**
 Ciota, Alexander 0148, 0888
 Ciota, Alexander T. 0589, 0599
 Cirera, Laia **1122**
 Cisneros-Pano, Jonathan 0174
 Cissé, Fatoumata 1192
 Cisse, Idrissa 0209
 Cissé, Idrissa 0718, 1139
 Cisse, Moussa B. **0012, 0744**
 Cisse, Moustapha 0254, 0926
 Cisteró, Pau 0405
 Cistero, Pau 0654
 Ciubotariu, Ilina I. **1102**
 C. Johansen, Igor 0838
 Clapp, Sheila 1143
 Clarence, Catherine 1151
 Clarisse, Ebene 0356, 0795
 Clark, Danielle 1208
 Clark, Eva 0381
 Clark, J.t. 1406
 Clark, Tanner 0024
 Clarke, Naomi 0038, 1237
 Clarke, Naomi E. 1243
 Clement, Andrea 1043
 Clennon, Julie A. 0864
 Clerinx, Jan 1288
 Cleveland, Dawn 1018
 Clifton, Kathryn **0939**
 Clish, Clary 1332
 Clish, Clary B. 1061
 Cloherty, Gavin 0007
 Coates, Emily 0849
 Cocker, Derek **0862**
 Coelho, Camila H. 0684
 Coello Escoto, Ana 0163, 1317
 Coetzee, Maureen 0841
 Coffey, Lark L. 0145, 0168
 Cogen, Anna L. 0380
 Coglianese, Nicole 0824
 Coh, Marcelina 0530
 Cohee, Lauren L. 1183
 Cohee, Lauren M. 0725, 0931
 Cohee, Lauren M. S. 0927
 Cohen, Adam 0097
 Cohen, Adam L. 0096, 0344, 0621
 Cohen, Adam L. 0987, 1298
 Cohen, Jessica 0882
 Cohen, Justin 0064, 0083, 0266
 Colborn, James 0259, 0282
 Colborn, Kathryn 0009, 1157, 1195
 Colby, Emily **0348**
 Coleman, Kristen K. 1364
 Colford, John M. 0897
 Colford Jr., John M. 0896
 Collado, Damaris 0474
 Collette, Nicole 0129
 Collins, Clinton 0926
 Collins, Jeffrey M. 1326
 Collins, Julie **0978**
 Collins, Katharine A. **0734**
 Collins, Matthew C. 0575
 Collins, Matthew H. 0595, 0596, 0893
 Colman, Fraser 1396
 Colmenares, Cecilia 0397
 Coloma, Josefina 0474, 0583
 Colston, Josh M. **0032, 0062**
 Colt, McKenzie 0213, 0641, 0641, 1057, **1066**
 Colt, Susannah 1286
 Colubri, Andres 0006, 0603
 Commons, Rob 0629
 Compaore, Cheick 0290, 0694
 Compaoré, Guillaume 0636
 Comsil Chochi, Federico 0293
 Conceicao, Jacilara **1340**
 Concu, Maura 0634
 Condé, Mohamed Saran 0278
 Condo, Patrick 0312, 0319
 Condori-Pino, Carlos 0540
 Conly, John M. 0024
 Conn, Dra. Jan 1188
 Conn, Jan E. 1005